This blog, written by Rosana Kapeller, CSO of Nimbus Therapeutics, is part of the “From the Trenches” feature of LifeSciVC. Early this week, Intercept Pharmaceuticals announced the much awaited design of their Ph. 3 clinical trial of Obeticholic Acid (OCA) in NASH (non-alcoholic steatohepatitis) with liver fibrosis (here). The trial, named REGENERATE, will be the first Ph. 3 trial ever in NASH… Read More